Top

Published in:

01-12-2020 | Maintenance Therapy | Review Article

Maintenance treatment in advanced HER2-negative gastric cancer

Authors: Y. Yao, R. Deng, D. Liao, H. Xie, J. Zuo, Y. Jia, F. Kong

Published in: Clinical and Translational Oncology | Issue 12/2020

Abstract

Survival for patients with advanced gastric cancer (GC) remains poor. Systemic chemotherapy which has reached a plateau stays the standard first-line (1L) treatment for advanced human epidermal growth-factor receptor 2 (HER2)-negative GC. To maximize the benefit of 1L treatment, the concept of maintenance treatment is constantly being explored. In advanced HER2-negative GC, current clinical guidelines do not recommend a standard maintenance therapy strategy. In addition to the monotherapy maintenance with fluorouracil after 4–6 cycles of 1L chemotherapy, some agents that are active against novel targets have been evaluated in clinical trials for maintenance treatment. Whereas most of these trials do not reach their primary endpoints, they open new horizons for the 1L treatment of advanced HER2-negative GC. Therefore, we reviewed the clinical trials in the field of maintenance treatment in advanced HER2-negative GC and discussed some of the problems in clinical trials.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590.CrossRefPubMed

Katai H, Ishikawa T, Akazawa K, Isobe Y, Miyashiro I, Oda I, et al. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007). Gastric Cancer. 2018;21(1):144–54. https://doi.org/10.1007/s10120-017-0716-7.CrossRefPubMed

Digklia A, Wagner AD. Advanced gastric cancer: current treatment landscape and future perspectives. World J Gastroenterol. 2016;22(8):2403–14. https://doi.org/10.3748/wjg.v22.i8.2403.CrossRefPubMedPubMedCentral

Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. https://doi.org/10.1016/S0140-6736(10)61121-X.CrossRefPubMed

Greig SL, Keating GM. Ramucirumab: a review in advanced gastric cancer. BioDrugs. 2015;29(5):341–51. https://doi.org/10.1007/s40259-015-0138-1.CrossRefPubMed

Scott LJ. Apatinib: a review in advanced gastric cancer and other advanced cancers. Drugs. 2018;78(7):747–58. https://doi.org/10.1007/s40265-018-0903-9.CrossRefPubMed

Yang L, Wang Y, Wang H. Use of immunotherapy in the treatment of gastric cancer. Oncol Lett. 2019;18(6):5681–90. https://doi.org/10.3892/ol.2019.10935.CrossRefPubMedPubMedCentral

Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019;30(1):19–33. https://doi.org/10.1093/annonc/mdy502.CrossRefPubMed

10.

NCCN. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology Gastric Cancer, Version 4. 2019. https://www.nccn.org/professionals/\(physician\_gls/default.aspx.\) 2019. Accessed 20 Dec 2019.

11.

Gridelli C, de Marinis F, Pujol J-L, Reck M, Ramlau R, Parente B, et al. Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2012;7(11):1713–21. https://doi.org/10.1097/JTO.0b013e318267cf84.CrossRefPubMed

12.

Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14(1):29–37. https://doi.org/10.1016/S1470-2045(12)70477-1.CrossRefPubMed

13.

Goey KKH, Elias SG, van Tinteren H, Laclé MM, Willems SM, Offerhaus GJA, et al. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study. Ann Oncol. 2017;28(9):2128–34. https://doi.org/10.1093/annonc/mdx322.CrossRefPubMed

14.

Qiu M-z, Wei X-l, Zhang D-s, Jin Y, Zhou Y-x, Wang D-s. Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation. Tumour Biol J Int Soc Oncodev Biol Med. 2014;35(5):4369–75. https://doi.org/10.1007/s13277-013-1574-5.CrossRef

15.

Eren OO, Ozturk MA, Sonmez OU, Oyan B. Safety, feasibility, and efficacy of capecitabine maintenance in patients with advanced gastric cancer: a retrospective study. Am J Ther. 2016;23(6):e1493–7. https://doi.org/10.1097/MJT.0000000000000156.CrossRefPubMed

16.

Wu J, Ryan T, Levinson B, Newman E, Hochster HS, Muggia F. Cisplatin with capecitabine: tolerance and activity in a phase I/II study preferentially enrolling patients with gastric cancer. Anticancer Res. 2012;32(3):939–45.PubMed

17.

Cancer Japanese Gastric, A. Japanese gastric cancer treatment guidelines, 5th edition. Gastric Cancer. 2018. https://doi.org/10.1007/s10120-020-01042-y.

18.

Park SR, Kim M-J, Nam B-H, Kim CG, Lee JY, Cho S-J, et al. A randomised phase II study of continuous versus stop-and-go S-1 plus oxaliplatin following disease stabilisation in first-line chemotherapy in patients with metastatic gastric cancer. Eur J Cancer. 2017;83:32–42. https://doi.org/10.1016/j.ejca.2017.06.008.CrossRefPubMed

19.

Lu Z, Zhang X, Liu W, Liu T, Hu B, Li W, et al. A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer. Gastric Cancer. 2018;21(5):782–91. https://doi.org/10.1007/s10120-018-0809-y.CrossRefPubMedPubMedCentral

20.

Haag G-M, Stocker G, Quidde J, Jaeger D, Lordick F. Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer—the multinational MATEO study. BMC Cancer. 2017;17(1):509. https://doi.org/10.1186/s12885-017-3497-9.CrossRefPubMedPubMedCentral

21.

Chung HC, Arkenau H-T, Lee J, Rha SY, Oh D-Y, Wyrwicz L, et al. Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. J Immunother Cancer. 2019;7(1):30. https://doi.org/10.1186/s40425-019-0508-1.CrossRefPubMedPubMedCentral

22.

Moehler M, Ryu M-H, Dvorkin M, Lee K-W, Coşkun HŞ, Wong R. Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design. Future Oncol. 2019;15(6):567–77. https://doi.org/10.2217/fon-2018-0668.CrossRefPubMed

23.

Moehler MH. Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2- advanced gastric or gastroesophageal junction cancer (GC/GEJC). https://meetings.asco.org/gi/abstracts-posters. 2020. Accessed 23 Jan 2020.

24.

Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29(30):3968–76. https://doi.org/10.1200/JCO.2011.36.2236.CrossRefPubMed

25.

Meulendijks D, de Groot JWB, Los M, Boers JE, Beerepoot LV, Polee MB, et al. Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study. Cancer. 2016;122(9):1434–43. https://doi.org/10.1002/cncr.29864.CrossRefPubMed

26.

Wöll E, Thaler J, Keil F, Gruenberger B, Hejna M, Eisterer W. Oxaliplatin/irinotecan/bevacizumab followed by docetaxel/bevacizumab in inoperable locally advanced or metastatic gastric cancer patients-\(AGMT\_GASTRIC-3\). Anticancer Res. 2017;37(10):5553–8. https://doi.org/10.21873/anticanres.11987.CrossRefPubMed

27.

Di Bartolomeo M, Niger M, Morano F, Corallo S, Antista M, Tamberi S, et al. Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. BMC Cancer. 2019;19(1):283. https://doi.org/10.1186/s12885-019-5498-3.CrossRefPubMedPubMedCentral

28.

Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, André T, Bennamoun M, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer The GERCOR OPTIMOX2 Study. J Clin Oncol. 2009;27(34):5727–33. https://doi.org/10.1200/jco.2009.23.4344.CrossRefPubMed

29.

André T, Tournigand C, Mineur L, Fellague-Chebra R, Flesch M, Mabro M, et al. Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. Ann Oncol. 2007;18(1):77–81. https://doi.org/10.1093/annonc/mdl336.CrossRefPubMed

30.

Cicero G, De Luca R, Dieli F. Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer. OncoTargets Ther. 2018;11:3059–63. https://doi.org/10.2147/OTT.S151276.CrossRef

31.

Giessen C, Laubender RP, Ankerst DP, Stintzing S, Modest DP, Mansmann U, et al. Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19(1):225–35. https://doi.org/10.1158/1078-0432.Ccr-12-1515.CrossRef

32.

Gyawali B, Hey SP, Kesselheim AS. A comparison of response patterns for progression-free survival and overall survival following treatment for cancer with PD-1 inhibitors: a meta-analysis of correlation and differences in effect sizes. JAMA Netw Open. 2018;1(2):e180416e. https://doi.org/10.1001/jamanetworkopen.2018.0416.CrossRef

33.

Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 Trial. JAMA Oncol. 2018;4(5):e180013e. https://doi.org/10.1001/jamaoncol.2018.0013.CrossRef

34.

Rojkó L, Reiniger L, Téglási V, Fábián K, Pipek O, Vágvölgyi A, et al. Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients. J Cancer Res Clin Oncol. 2018;144(7):1219–26. https://doi.org/10.1007/s00432-018-2642-4.CrossRefPubMed

35.

Song Z, Yu X, Zhang Y. Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma. Lung Cancer. 2016;99:166–71. https://doi.org/10.1016/j.lungcan.2016.07.013.CrossRefPubMed

36.

Bang YJ, Cho JY, Kim YH, Kim JW, Di Bartolomeo M, Ajani JA, et al. Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23(19):5671–8. https://doi.org/10.1158/1078-0432.Ccr-17-0025.CrossRef

Title: Maintenance treatment in advanced HER2-negative gastric cancer
Authors: Y. Yao
R. Deng
D. Liao
H. Xie
J. Zuo
Y. Jia
F. Kong
Publication date: 01-12-2020
Publisher: Springer International Publishing
Keywords: Maintenance Therapy
Gastric Cancer
Gastric Cancer
Bevacizumab
Cytostatic Therapy
Published in: Clinical and Translational Oncology / Issue 12/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-020-02379-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2020

Indicators of a pro-tumor immune response are evident at early stages of breast cancer

Cytotoxic T lymphocyte antigen-4 (CTLA-4) expression in chordoma and tumor-infiltrating lymphocytes (TILs) predicts prognosis of spinal chordoma

Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer

100% peer review in radiation oncology: is it feasible?

Potential roles of lymphovascular space invasion based on tumor characteristics provide important prognostic information in T1 tumors with ER and HER2 positive breast cancer

The free amino acid profiles and metabolic biomarkers of predicting the chemotherapeutic response in advanced sarcoma patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer